Bluebird’s Zynteglo Approval Kicks Off Commercial Operations
Beta-Thalassemia Gene Therapy’s List Price Is $2.8m
Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.
